 "Pfizer stops production at Tamil Nadu plant after 11 USFDA observations")
Pfizer's manufacturing facility in Tamil Nadu’s Sriperumbudur is not following quality control norms and lacks data related to laboratory records. These are among the 11 observations the US Food and Drug Administration (USFDA) has made following inspections at the Hospira Healthcare India in Sriperumbudur conducted in last March-April.
The company said it had “voluntarily paused” production in the facility, which became a part of Pfizer following its acquisition of US-based Hospira in February 2015 in a $17-billion deal.
A Pfizer spokesperson said they were disappointed with the outcome of the drug regulator’s inspection. “We have submitted a comprehensive response to the USFDA and are committed to implementing the necessary improvements and ensuring the quality of our medicines. Pfizer is committed to product quality and we have voluntarily paused production at our Irungattukottai site.”
The facility had earlier received observations from the USFDA as part of inspections in 2013 and 2015, according to reports.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%